Dermal Fillers: Types, Real Risks, and the Emergency Signs Everyone Should Know Before Injection

Evidence reviewed to Aug 2026

This page explains what dermal fillers are, how they differ, what "reversible" really means, and where the FDA draws its hard lines. It is informational only and is not medical advice. Whether a filler is right for you, in which anatomy, and at what volume are medical judgments for a licensed clinician. Nobody associated with this publication has received or performed any filler treatment; every number below is attributed to the source that measured it.

What are dermal fillers, and how does the FDA regulate them?

Dermal fillers — also called soft-tissue fillers, injectable implants, or wrinkle fillers — are, in the FDA's own words, "medical device implants approved by the FDA for use in helping to create a smoother and/or fuller appearance in the face." High · FDA device page That word device matters: unlike botulinum toxin, which is a prescription drug, most fillers are regulated as medical devices, and aesthetic dermal fillers are Class III — the FDA's highest-scrutiny device class, reviewed through the premarket approval (PMA) pathway (FDA Clinical Overview of Dermal Fillers; FDA Product Classification, product code LMH) [1][2][8].

The FDA has approved fillers only for adults "22 years of age or older (over the age of 21)," and only for specific uses: absorbable fillers for moderate-to-severe facial wrinkles and folds such as nasolabial folds (the lines from the sides of the nose to the corners of the mouth) and perioral lines (the fine wrinkles around the mouth); augmentation of the lips, cheeks, chin, and the back of the hand; non-absorbable (permanent) fillers for nasolabial folds and cheek acne scars only; correction of facial fat loss (lipoatrophy) in people with HIV; and correction of contour deficiencies such as wrinkles and acne scars [1]. Anything outside that list is an unapproved use, and the FDA states plainly that "the risks associated with unapproved uses of dermal fillers, or with the use of unapproved products are not known" [1].

What types are there, and which ones can be dissolved?

Not all fillers are the same material, and the material determines both how long the result lasts and — crucially — whether it can be removed if something goes wrong. The three families a consumer will encounter:

The duration figures for HA are not marketing estimates: the FDA's Clinical Overview reports that "the duration of effect reported in approved PMAs ranges from" six months (Belotero Balance) to 24 months (Juvederm Voluma in the cheek) [2]. The non-HA durations, by contrast, are the manufacturers' own claims — Merz says Radiesse results "have been shown to last up to 2 years" [9], and Galderma reports Sculptra study participants had "sustained results for up to 2 years" [10] — so read them as a best case, not a labeled range. The reversibility column is the safety story. Because HA is a substance the body already produces, the FDA notes that "the effects of HA may be reversed using enzymatic degradation by hyaluronidase, as advocated by some professional societies" [2]. Calcium hydroxylapatite and PLLA have no such off-switch. "Dissolvable" is not a footnote; it is a safety feature.

How well do they work, and what are they approved to do?

Fillers are among the most common non-surgical procedures performed in the United States. The American Society of Plastic Surgeons (ASPS) counted 5,331,426 hyaluronic-acid filler patients in its 2024 Plastic Surgery Statistics Report [7]. For the specific, on-label job of adding volume and softening folds in the mid-face and around the mouth, the FDA's approvals rest on "controlled, clinical study of these products when used in the face or hand" [1]. High · FDA device page

Two honest limits sit alongside that. The FDA states that "the safe use of these products in combination with neuromodulators ('Botox') or other treatments has not been evaluated in a controlled, clinical study," and that "the safety of these products used repeatedly over a long period of time has not been evaluated in a controlled, clinical study" [1]. In plain terms: the pivotal trials measured single-course use in defined facial areas, not years of stacked treatments across the whole face.

What are the risks, from common to catastrophic?

Fillers carry a spectrum of risk. Most of it is minor and self-resolving; a thin slice of it is disfiguring or dangerous. Ranking it honestly, common to rare, per the FDA's own device page [1]:

The FDA is unambiguous about which risk to take most seriously: "The most concerning risk associated with the use of dermal fillers is unintentional injection into a blood vessel, leading to blocked blood vessels and poor blood supply to tissues. While the chances of this happening are low, if it does happen, the resulting complications can be serious and may be permanent" [1]. Its 2015 labeling guidance spells out the mechanism — "embolization, occlusion of the vessels, ischemia, or infarction" — and the consequences: "temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, and damage to underlying facial structures" [2].

This is not only a labeling-page concern. A 2024 review in Annals of Emergency Medicine, titled "Cosmetic Filler–Induced Vascular Occlusion: A Rising Threat Presenting to Emergency Departments," documents these injuries reaching emergency departments as filler use grows, with sequelae that "range from disfiguring skin necrosis to blindness and stroke" (Soares et al., 2024) [3]. Moderate · clinical review It is rare on a per-injection basis and real enough that emergency physicians are being taught to recognize it.

What does "reversible" actually mean?

For HA fillers, reversibility is genuine. The enzyme hyaluronidase breaks HA down, and the FDA acknowledges this reversal "as advocated by some professional societies" [2]. In a suspected vascular occlusion, injecting hyaluronidase to dissolve the offending HA is a core part of the emergency response described in the clinical literature [3].

Reversibility has limits worth stating plainly. Hyaluronidase works on hyaluronic acid — it does nothing for calcium hydroxylapatite, poly-L-lactic acid, or permanent fillers. And dissolving is itself a medical procedure: it uses a prescription enzyme whose own FDA labeling covers other uses entirely and notes that allergic and anaphylactic-like reactions "have been reported, rarely" [11] — and the enzyme cannot tell wanted filler from unwanted. The FDA is blunt about permanent products: "it may be difficult or impossible to remove the filler material, especially 'permanent' fillers, or fillers that are not made of materials such as hyaluronic acid" [1]. The takeaway for a consumer choosing among products: ask which family you are getting, and whether it can be reversed at all.

The hard lines the FDA draws

Several practices are marketed to consumers that the FDA explicitly warns against. These are not gray areas.

• No needle-free "hyaluron pens." The FDA warns the public and providers not to use needle-free devices to inject fillers, stating it "is aware of serious adverse events" [1]; its October 2021 safety communication describes "serious injuries and in some cases, permanent harm to the skin, lips, or eyes" [4]. The American Academy of Dermatology reinforces this: using a needle-free device near the eyes "can put too much pressure on the eye, causing permanent eye damage or blindness," and it can cause "lumpy, unevenly shaped lips," necrosis, scarring, infection, and stroke. Its advice is direct: "DO NOT use DIY needle-free devices to inject fillers" [5]. High · FDA + AAD
• No over-the-counter or self-injected filler. "Do not inject yourself with dermal fillers," the FDA says, and "do not purchase dermal filler products online, because they could be counterfeit products or products that are not approved for use in the U.S." The agency has not approved any filler for OTC use [1].
• No body contouring. The FDA "recommends against using dermal fillers or any injectable filler for body contouring and enhancement," specifically to increase breast size, enlarge the buttocks, or add fullness to the feet, and against injection into bone, tendon, ligament, or muscle. It also lists the glabella, nose, area around the eyes, forehead, and neck as areas it has not approved [1].
• No injectable silicone for aesthetics. Injectable silicone "is not approved for any aesthetic procedure," and the FDA links it to "long term pain, infections, and serious injuries, such as scarring and permanent disfigurement, embolism…, stroke, and death" [1].

Who should inject, and where does it matter?

The FDA frames filler as "a medical procedure, not a cosmetic treatment," and recommends seeking "a licensed health care provider with experience in the fields of dermatology or plastic surgery" who is trained in the specific procedure [1]. It advises asking directly about a provider's training and experience injecting fillers in the face and hands, and knowing that the provider has a plan for managing a vascular event should one occur [1]. Who may legally inject, and under what medical supervision, varies by state — a separate question this publication covers in who can legally inject, alongside how to verify a license. What does not vary is that this is medicine, and the person holding the syringe should be qualified to recognize and treat the rare emergency described above.

What does it cost?

The American Society of Plastic Surgeons' consumer cost page, drawing on what it calls its latest member statistics, lists average costs of $715 for hyaluronic-acid filler, $901 for non-HA filler, and $743 for lip augmentation with filler [6]. Moderate · ASPS cost page ASPS is explicit that the price varies with the qualifications of the person injecting, the procedure, the time it takes, and geography, and that health insurance does not cover it [6]. A national average tells you little about what one clinic charges for one syringe — but a price so far below these figures that it could not plausibly cover a genuine FDA-approved product plus a qualified injector is a signal worth questioning, for the same reasons laid out in the red flags of too-cheap injectables: the FDA has repeatedly warned about counterfeit filler products marketed in the U.S. [1].

What we don't know

Stated plainly, and dated to August 2026:

• The FDA notes that the long-term safety of repeated filler use "over a long period of time has not been evaluated in a controlled, clinical study," and neither has combining filler with botulinum toxin or other treatments in the same visit [1].
• Safety in pregnancy, while breastfeeding, in people under 22, and in those prone to keloid or hypertrophic scarring is described by the FDA as "unknown" [1].
• The true per-injection rate of vascular occlusion is not precisely established; the literature describes it as rare but rising in absolute numbers as filler volume grows [3].
• Late-onset reactions can appear "weeks, months, or years after injection," and the full picture of what triggers them is still emerging [1].

The bottom line

Dermal fillers are effective, well-studied medical devices for a defined set of facial jobs, and their everyday side effects are minor. The reason to slow down is the rare event at the far end of the risk ladder — filler in a vessel — which is why the material (reversible or not), the injector's qualifications, the injection site, and your own knowledge of the emergency signs are the levers that actually move safety. None of that is a decision a website can make for you. It is a conversation to have with a licensed clinician, and this page exists to make that conversation sharper.

References

1. U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). Content current as of July 6, 2023.
2. U.S. Food and Drug Administration. Clinical Overview of Dermal Fillers (device panel materials), including the 2015 FDA Safety Communication on the risk of intravascular filler injection.
3. Soares DJ, et al. Cosmetic Filler–Induced Vascular Occlusion: A Rising Threat Presenting to Emergency Departments. Annals of Emergency Medicine. 2024;83(1):59-67. PMID 37565956.
4. U.S. Food and Drug Administration. Do Not Use Needle-Free Devices for Injection of Dermal Fillers — FDA Safety Communication (FDA bulletin, October 8, 2021; the original safety communication page has been archived by the FDA).
5. American Academy of Dermatology. Needle-free fillers: The risks you need to know about.
6. American Society of Plastic Surgeons. Dermal Fillers Cost (consumer cost page; national averages from ASPS member statistics).
7. American Society of Plastic Surgeons. 2024 Plastic Surgery Statistics Report (hyaluronic-acid filler patient volume).
8. U.S. Food and Drug Administration. Product Classification: implant, dermal, for aesthetic use (product code LMH) — Device Class 3, premarket approval (PMA).
9. Merz Aesthetics. Radiesse — Frequently Asked Questions (manufacturer duration claim).
10. Galderma. Sculptra — Frequently Asked Questions (manufacturer duration claim).
11. U.S. Food and Drug Administration. Hylenex recombinant (hyaluronidase human injection) — Prescribing Information (labeled indications and hypersensitivity reports).

Update log

• 2026-08-05 — First published. Every claim checked against FDA device labeling and product classification, the 2024 Annals of Emergency Medicine review, FDA and AAD needle-free-device warnings, manufacturer duration claims, the Hylenex prescribing information, and ASPS fee and volume data.